display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
mBC - TNBC - L1 - all population
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus nab-paclitaxel IMpassion-130 ...
atezolizumab plus paclitaxel IMpassion-131 ...
pembrolizumab based treatment
pembrolizumab plus SoC KEYNOTE-355 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons